IHC can detect changes at the protein level that result not only from gene aberrations, most commonly gene amplifications, but also from specific DNA rearrangements or point mutations (such as EML4-ALK translocation in non-small cell lung cancer (NSCLC) and IDH1/2 mutations in glioma) [5–7]. Here, IDH1 is linked to non-small cell lung carcinoma.